Arts

Books

Fashion & Beauty

Performing Arts

Food

Visual Arts

Design

Business

Entrepreneurship

Investing

Marketing

Careers

Management

Non-Profit

Comedy

Stand-Up

Comedy Interviews

Improv

Education

Self-Improvement

How To

Courses

Language Learning

Fiction

Comedy Fiction

Drama

Science Fiction

Government

Health & Fitness

Medicine

Alternative Health

Nutrition

Mental Health

Fitness

Sexuality

History

Kids & Family

Parenting

Stories for Kids

Education for Kids

Pets & Animals

Leisure

Video Games

Games

Automotive

Animation & Manga

Hobbies

Aviation

Home & Garden

Crafts

Music

Music Commentary

Music Interviews

Music History

News

Sports News

Entertainment News

News Commentary

Politics

Daily News

Business News

Tech News

Religion & Spirituality

Christianity

Spirituality

Religion

Judaism

Islam

Buddhism

Hinduism

Science

Social Sciences

Life Sciences

Natural Sciences

Nature

Chemistry

Mathematics

Earth Sciences

Physics

Astronomy

Society & Culture

Documentary

Relationships

Philosophy

Personal Journals

Places & Travel

Sports

Golf

Soccer

Wrestling

Basketball

Football

Fantasy Sports

Baseball

Wilderness

Running

Hockey

Rugby

Cricket

Volleyball

Tennis

Swimming

Technology

True Crime

TV & Film

Film Interviews

TV Reviews

After Shows

Film Reviews

Film History

Healthcare communications and digital marketing veterans Buddy Scalera, Matt Balogh, and Chris Cullmann discusses marketing in the age of digital health.  Buddy, Matt, and Chris host interviews and identify the most relevant technology, trends, and news impacting pharmaceutical and healthcare today.

Healthcare communications and digital marketing veterans Buddy Scalera, Matt Balogh, and Chris Cullmann discusses marketing in the age of digital health. Buddy, Matt, and Chris host interviews and identify the most relevant technology, trends, and news impacting pharmaceutical and healthcare today.

Rx Digital Marketing Podcast

SUNY Downstate College of Medicine Lecture Series

College of Medicine Lecture Series

爱米尔·库埃是心理暗示术早期研究与实践者之一，被称为“自我暗示之父”。他通过《超级心理暗示术》[1] 一书向读者传授了如何积极运用自我暗示的魔力，改变自己和他人的身心，过一种积极健康的生活。 希尔在其励志进修书目中特别推荐《超级心理暗示术》，并一直成为许多西方心灵大师的必读之作。 爱米尔·库埃1857年2月26日出生于法国奥布地区的特鲁瓦。母亲是香巴尼人，父亲是布里托尼人，在东部的一家公司工作。爱米尔15岁才进入镇上的一所中学读书，毕业前完成了所有理科课程。 19岁时，他成为一家药店学徒，后到巴黎一所医药大学攻读化学专业。1882年返回家乡，开了一家药店。1884年结婚后在妻子的建议下跟随利博尔特博士学习催眠术，后不断实践，开始研究暗示与自我暗示，形成了一套自己的暗示与自我暗示方法。他将这些方法用于病人身上，成功医治了很多医院无法救治的病人。他还和妻子一道创建了南希催眠学院，被尊称为“自我暗示之父”。 此后，他的影响越来越大，每年要接待15000多名病人，还应邀到美国和其他国家演讲，他每次演讲都广受欢迎，讲座现场犹如朝圣一样。 本书是关于暗示和自我暗示的一本经典之作，著名成功大师拿破仑。希尔在其励志进修书目中特别推荐此书，并一直成为许多西方心灵大师的必读之作。

新慧读书 | 超级心理暗示术

Coffee Talk Podcast is a fun, informative, and sometimes serious podcast for and by first responders, our families, supporters, and communities.

Ann Martgan's Coffee Talk

MedicusPodden

On DOUBLE DOSE Dr. Trish and PA Jeff discuss trending medical topics, conduct interviews with highly respected specialists in multiple fields of study, as well as profiles  of interesting patients that we have been honored to treat

Trish Hurford is a Board Certified Physical Medicine and Rehabilitation Physician based in St. Louis Missouri.  She specializes in the treatment of Musculoskeletal injuries and disfunction, with an interest in non-operative treatments of Neck and Back injuries and pathology.

Jeff Todd, is a Certified Physicians Assistant also based in St. Louis Missouri.  Jeff has over 11 years of experience as an Athletic Trainer at the Division 1 collegiate level, as well as over 10 years of clinical experience in the field of Orthopedics & Sports Medicine as a Physicians Assistant.

Together in the office and now on the Podcast, they work together to help educate, and entertain with hopes of helping people live a happier, healthier life.

On DOUBLE DOSE Dr. Trish and PA Jeff discuss trending medical topics, conduct interviews with highly respected specialists in multiple fields of study, as well as profiles of interesting patients that we have been honored to treat Trish Hurford is a Board Certified Physical Medicine and Rehabilitation Physician based in St. Louis Missouri. She specializes in the treatment of Musculoskeletal injuries and disfunction, with an interest in non-operative treatments of Neck and Back injuries and pathology. Jeff Todd, is a Certified Physicians Assistant also based in St. Louis Missouri. Jeff has over 11 years of experience as an Athletic Trainer at the Division 1 collegiate level, as well as over 10 years of clinical experience in the field of Orthopedics & Sports Medicine as a Physicians Assistant. Together in the office and now on the Podcast, they work together to help educate, and entertain with hopes of helping people live a happier, healthier life.

On DOUBLE DOSE Dr. Trish and PA Jeff discuss trending medical topics, conduct interviews with highly respected specialists in multiple fields of study, as well as profiles  of interesting patients that we have been honored to treat

Trish Hurford is a Board Certified Physical Medicine and Rehabilitation Physician based in St. Louis Missouri.  She specializes in the treatment of Musculoskeletal injuries and disfunction, with an interest in non-operative treatments of Neck and Back injuries and pathology.

Jeff Todd, is a Certified Physicians Assistant also based in St. Louis Missouri.  Jeff has over 11 years of experience as an Athletic Trainer at the Division 1 collegiate level, as well as over 10 years of clinical experience in the field of Orthopedics &amp; Sports Medicine as a Physicians Assistant.

Together in the office and now on the Podcast, they work together to help educate, and entertain with hopes of helping people live a happier, healthier life.

DOUBLE DOSE

Drugwatcher (https://www.drugwatcher.org/) keeps the public up-to-date on litigation around defective medications and medical devices.

Drugwatcher

Podcast dedicado a criar conteúdos em áudios curtos e objetivos, para estudar para as provas de Residência Médica.

Projeto Residência

Two friends living across the country try and bring laughter and knowledge to you wonderful humans.

R Experience Podcast

Rupa Sarkar, Editor-in-Chief, Diana Samuel, Deputy Editor, Lucy Dunbar, Senior Editor, and Gustavo Monnerat, Senior Editor at The Lancet Digital Health, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.&nbsp; A monthly audio companion to this open access journal, this podcast covers a broad range of topics, from using machine learning to predict mortality in prostate cancer and the need for feminist intersectionality in digital health, to how algorithms can predict a patient's race from medical data, and more.

Rupa Sarkar, Editor-in-Chief, Diana Samuel, Deputy Editor, Lucy Dunbar, Senior Editor, and Gustavo Monnerat, Senior Editor at The Lancet Digital Health, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.  A monthly audio companion to this open access journal, this podcast covers a broad range of topics, from using machine learning to predict mortality in prostate cancer and the need for feminist intersectionality in digital health, to how algorithms can predict a patient's race from medical data, and more.

The Lancet Digital Health in conversation with

Podcast voltado para a educação em saúde do grupo de gestantes da Usf Doron, extensivo aos parceiros, familiares e demais interessados.

Papo de Gestante

O Podcast Dominatrês é um projeto colaborativo idealizado por três profissionais de saúde com especialização em sexualidade humana, na intenção de trazer a discussão sobre o tema dentro de diferentes escopos. Além da visão biológica da sexualidade, o podcast analisa e discute de forma descontraída a sexualidade em recortes culturais, nas expressões artísticas, movimentos sociais e trazendo o discurso da diversidade para as perspectivas.

Dominatrês

“The happier you are the more beautiful you become”. Our aim is to bring happiness in each and everyone who comes to consult us. Beauty is what we want to achieve and our path lies on the pursuit of happiness. We believe in scientific analysis, genuine and ethical opinion to provide our patients with the most suitable options. Excellence in work, ethics in profession and empathy for patients is our code. 
Through this podcast we aim to educate by providing correct information and our understanding and views of cosmetic, aesthetic and plastic medicine to everyone who listens to this podcast.

“The happier you are the more beautiful you become”. Our aim is to bring happiness in each and everyone who comes to consult us. Beauty is what we want to achieve and our path lies on the pursuit of happiness. We believe in scientific analysis, genuine and ethical opinion to provide our patients with the most suitable options. Excellence in work, ethics in profession and empathy for patients is our code. Through this podcast we aim to educate by providing correct information and our understanding and views of cosmetic, aesthetic and plastic medicine to everyone who listens to this podcast.

Handa Aesthetics and Plastics

Der Podcast Rund um das Thema Fußgesundheit!
Ihr hörst du mich und meine Gäste über das Thema Fußgesundheit und gelegentlich auch über Physiotherapie im Allgemeinen sprechen.
Ja unsere Füße sind unser Fundament und doch lässt das Wissen, über ihre Funktion sowie Fähigkeiten, zu wünschen übrig. 
"Hätte ich das mal früher gewusst!" ist einer der häufigsten Sätze, die ich in meinem Praxisalltag von den Patienten höre. 
Ich möchte aufklären und das ein oder andere Ammenmärchen beleuchten. 
Des Weiteren erlebt die Physiotherapie gerade einen wunderschönen Wandel. Immer lauter werden die Stimmen, dass sich die Patienten von den Liegen erheben und in die Aktivität und Körperwahrnehmung gehen sollen. 
Und hier hört ihr meine Stimme dazu! :-)
Eure Lara

Der Podcast Rund um das Thema Fußgesundheit! Ihr hörst du mich und meine Gäste über das Thema Fußgesundheit und gelegentlich auch über Physiotherapie im Allgemeinen sprechen. Ja unsere Füße sind unser Fundament und doch lässt das Wissen, über ihre Funktion sowie Fähigkeiten, zu wünschen übrig. "Hätte ich das mal früher gewusst!" ist einer der häufigsten Sätze, die ich in meinem Praxisalltag von den Patienten höre. Ich möchte aufklären und das ein oder andere Ammenmärchen beleuchten. Des Weiteren erlebt die Physiotherapie gerade einen wunderschönen Wandel. Immer lauter werden die Stimmen, dass sich die Patienten von den Liegen erheben und in die Aktivität und Körperwahrnehmung gehen sollen. Und hier hört ihr meine Stimme dazu! :-) Eure Lara

Lamovere der Podcast

Dr. Scott Gray-The Sport and Spine Physical Therapist

Fragile, Not Broken is produced and hosted by A Rosie Place for Children in South Bend, Indiana.  The podcast is a voice for children who are medically fragile and their families.  For more information visit arosieplace.org

Fragile, Not Broken is produced and hosted by A Rosie Place for Children in South Bend, Indiana. The podcast is a voice for children who are medically fragile and their families. For more information visit arosieplace.org

Fragile, Not Broken - A Rosie Place for Children

Health Break is a podcast dedicated to the health and wellness of Polk County Public Schools Employees. Host Erin Zimmer, also a Wellness Coach for PCPS, and her guests talk about insurance benefits, open enrollment, our Employee Health Centers and all that they offer, and our wellness programs – all to promote good health and lifestyle choices in our employees. If you have a specific health and wellness question, ask it at wellness.polkschoolsfl.com and it may appear on a future show! Let’s take a journey to better health together!

Health Break

Podcast – Die Rettungsaffen

Explore the unpredictable and demanding world of parenting with husband-and-wife duo, Drs. Adam and Jaclyn Dovico! As an educator (Adam), pediatrician (Jaclyn), and parents ourselves, we understand the joys and challenges of raising children. Join us as we talk candidly about parenting in a digital age and ways that you can raise happy and healthy children. Remember, there is no such thing as a perfect parent, but you can be the best parent for your child.&nbsp;

Explore the unpredictable and demanding world of parenting with husband-and-wife duo, Drs. Adam and Jaclyn Dovico! As an educator (Adam), pediatrician (Jaclyn), and parents ourselves, we understand the joys and challenges of raising children. Join us as we talk candidly about parenting in a digital age and ways that you can raise happy and healthy children. Remember, there is no such thing as a perfect parent, but you can be the best parent for your child. 

EdMed Talks

Welcome of taking charge of my cancer podcast, the podcast designed to be your trusted companion on the path to a higher quality of life during your cancer journey. Hosted by empathetic experts and individuals who have triumphed over cancer themselves, this show is a beacon of hope, inspiration, and tangible solutions for you while navigating the twists and turns after your cancer diagnosis.

Taking Charge of My Cancer

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

Malaria Vaccine

The future of medicine is here! You will be amazed to learn what's possible when you step outside the box of Western Medicine. Take your first step. <a href="https://drapro.substack.com?utm_medium=podcast">drapro.substack.com</a>

The future of medicine is here! You will be amazed to learn what's possible when you step outside the box of Western Medicine. Take your first step. drapro.substack.com

The future of medicine is here! You will be amazed to learn what's possible when you step outside the box of Western Medicine. Take your first step. <a href="https://drapro.substack.com?utm_medium=podcast" rel="noopener noreferrer">drapro.substack.com</a>

Quantum Waves of Wellness

Der Männerpodcast der Österreichischen Krebshilfe

Männer gehen weniger zum Arzt, erkranken öfter an Krebs, sterben früher. Und reden? Tun sie eher selten. Zeit, das zu ändern. 
Alexander Greiner (Journalist) und Martina Löwe (Geschäftsführerin Österreichische Krebshilfe) sprechen mit Menschen, die offen mit Krebs umgehen, die sich der Vorsorgeuntersuchung stellen, für die Krebs zum Alltag gehört. 

Was hilft bei Krebs, vor allem Männern? Darum geht es in diesem Podcast.

Credits:
Hosts: Martina Löwe und Alexander Greiner; Redaktion: Paulin Klärner, big5health; Technik: Felix Kirsch, ungefiltert; Produktion: big5health

#wirredendrüber

Der Männerpodcast der Österreichischen Krebshilfe Männer gehen weniger zum Arzt, erkranken öfter an Krebs, sterben früher. Und reden? Tun sie eher selten. Zeit, das zu ändern. Alexander Greiner (Journalist) und Martina Löwe (Geschäftsführerin Österreichische Krebshilfe) sprechen mit Menschen, die offen mit Krebs umgehen, die sich der Vorsorgeuntersuchung stellen, für die Krebs zum Alltag gehört. Was hilft bei Krebs, vor allem Männern? Darum geht es in diesem Podcast. Credits: Hosts: Martina Löwe und Alexander Greiner; Redaktion: Paulin Klärner, big5health; Technik: Felix Kirsch, ungefiltert; Produktion: big5health #wirredendrüber

Das Herrenzimmer

En Apasionadas, la Dra. Maite Fernández te acompaña a que hagas un viaje por el universo femenino en el que aprenderás sobre salud vaginal, sexualidad femenina, relaciones de pareja y muchas cosas más. 

Con una base científica, pero en un tono divertido para que lo pases bien a la vez que aprendes. CADA DOMINGO por la mañana tienes una cita para SENTIR y APRENDER. 

Un podcast enfocado a mujeres, pero EL GRAN BENEFICIO PARA LA HUMANIDAD es que lo escuchen también los hombres. ¡NO TE LO PUEDES PERDER!

Si quieres estar al día de todo y no perderte ningún capítulo, suscríbete a mi newsletter en: https://apasionadas.typeform.com/suscribete 

También puedes visitar mi web www.dramaitefernandez.com , donde encontrarás más contenido de valor.

¡Sígueme! 
✨Instagram: @dramaitefernandez 
✨Youtube: www.youtube.com/@dramaitefernandez

Recuerda seguir mi podcast y dejar una reseña. ¡Estaré encantada de leerte! 🌸

En Apasionadas, la Dra. Maite Fernández te acompaña a que hagas un viaje por el universo femenino en el que aprenderás sobre salud vaginal, sexualidad femenina, relaciones de pareja y muchas cosas más. Con una base científica, pero en un tono divertido para que lo pases bien a la vez que aprendes. CADA DOMINGO por la mañana tienes una cita para SENTIR y APRENDER. Un podcast enfocado a mujeres, pero EL GRAN BENEFICIO PARA LA HUMANIDAD es que lo escuchen también los hombres. ¡NO TE LO PUEDES PERDER! Si quieres estar al día de todo y no perderte ningún capítulo, suscríbete a mi newsletter en: https://apasionadas.typeform.com/suscribete También puedes visitar mi web www.dramaitefernandez.com , donde encontrarás más contenido de valor. ¡Sígueme! ✨Instagram: @dramaitefernandez ✨Youtube: www.youtube.com/@dramaitefernandez Recuerda seguir mi podcast y dejar una reseña. ¡Estaré encantada de leerte! 🌸

Apasionadas. El podcast de la Dra. Maite Fernández

Leukemia - The Bloodline With Blood Cancer United Podcast

Weekly audio newsletter about vaccines and public health—clear science and meaningful conversations for health professionals, science communicators, policymakers, and anyone who wants to stay informed. <a href="https://communityimmunity.substack.com?utm_medium=podcast">communityimmunity.substack.com</a>

Weekly audio newsletter about vaccines and public health—clear science and meaningful conversations for health professionals, science communicators, policymakers, and anyone who wants to stay informed. communityimmunity.substack.com

Weekly audio newsletter about vaccines and public health—clear science and meaningful conversations for health professionals, science communicators, policymakers, and anyone who wants to stay informed. <a href="https://communityimmunity.substack.com?utm_medium=podcast" rel="noopener noreferrer">communityimmunity.substack.com</a>

Community Immunity

Dedicated to uncovering clinical developments and treatment advancements in the field of rheumatology, Living Rheum delivers expert insights on patient management across a broad spectrum of rheumatic diseases, such as rheumatoid arthritis, lupus, scleroderma, osteoporosis, and more.

Living Rheum

L’Associazione Piccoli Punti ETS, grazie alla collaborazione di -Sphera Holding- e del Comune di Padova - Ufficio Città Sane e con il patrocinio dell’Università degli Studi di Padova, ha realizzato il podcast in 14 puntate -Mappa del Melanoma in Piccoli Punti-.
Il progetto parte dalla convinzione che una migliore conoscenza dei fattori di rischio del melanoma e una maggiore comprensione del suo vocabolario possano avere un ruolo attivo nella prevenzione e nel controllo della malattia. 
L’intento è quello di favorire migliori possibilità di cura, come suggeriscono numerosi studi sull’ “empowerment” (consapevolezza attiva) in oncologia. Infatti, l’acquisizione di concetti di base permette al paziente con melanoma di affrontare meglio e con maggiore beneficio le informazioni mediche relative al trattamento del tumore.

L’Associazione Piccoli Punti ETS, grazie alla collaborazione di -Sphera Holding- e del Comune di Padova - Ufficio Città Sane e con il patrocinio dell’Università degli Studi di Padova, ha realizzato il podcast in 14 puntate -Mappa del Melanoma in Piccoli Punti-. Il progetto parte dalla convinzione che una migliore conoscenza dei fattori di rischio del melanoma e una maggiore comprensione del suo vocabolario possano avere un ruolo attivo nella prevenzione e nel controllo della malattia. L’intento è quello di favorire migliori possibilità di cura, come suggeriscono numerosi studi sull’ “empowerment” (consapevolezza attiva) in oncologia. Infatti, l’acquisizione di concetti di base permette al paziente con melanoma di affrontare meglio e con maggiore beneficio le informazioni mediche relative al trattamento del tumore.

Mappa Del Melanoma in Piccoli Punti

Our Untangled Minds by CUSM is a student-run medical education podcast with the goal of creating episodes to further explore our medical profession and expand upon the medical topics that we encounter in our everyday experiences and conversations.

Our Untangled Minds

Innovación en el control de la hipercolesterolemia

Ak9Demia

A podcast dedicated to helping you look better, feel better, and BE better. Hosted by the Mojo Vitality medical team from Atlanta, Georgia led by Dr. James Cullison - we cover all the latest trends in weight loss, hormone therapy, sexual dysfunction, pelvic wellness, and health and fitness.

A podcast dedicated to helping you look better, feel better, and BE better. Hosted by the Mojo Vitality medical team from Atlanta, Georgia led by Dr. James Cullison - we cover all the latest trends in weight loss, hormone therapy, sexual dysfunction, pelvic wellness, and health and fitness.

The Mojo Podcast Studio

Travel Health Podcasts by Pyllola"Travel Health" is the essential guide for healthcare tourism, maintaining well-being while exploring the globe! It is your in-pocket travel clinic and covers vital topics for travelers, including the management of chronic conditions and health risks abroad, dietary advice during travel, and prevalent travel-related illnesses. Our experts offer priceless knowledge, share their own experiences, and give practical advice to tackle health issues with particular emphasis on Italy.<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pyllola.com">Pyllola </a>is a primary care provider specialized in primary healthcare for tourists and travelers in Italy, offering instant medical care by English-speaking doctors via an online visit.Pyllola offers the best way to see a physician in Italy as a tourist assuring best healthcare for travelers.​for more insights on travel related health issues please check our <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pyllola.com/blog">blog </a>at <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pyllola.com">Pyllola's </a>websitePlease consider that this podcast is solely for informational purposes and should not be regarded as medical advice or a recommendation for any medication or treatment. It is essential that your doctor assesses your condition and, if necessary, prescribes the appropriate treatment.

Travel Health Podcasts by Pyllola "Travel Health" is the essential guide for healthcare tourism, maintaining well-being while exploring the globe! It is your in-pocket travel clinic and covers vital topics for travelers, including the management of chronic conditions and health risks abroad, dietary advice during travel, and prevalent travel-related illnesses. Our experts offer priceless knowledge, share their own experiences, and give practical advice to tackle health issues with particular emphasis on Italy. Pyllola is a primary care provider specialized in primary healthcare for tourists and travelers in Italy, offering instant medical care by English-speaking doctors via an online visit. Pyllola offers the best way to see a physician in Italy as a tourist assuring best healthcare for travelers.​ for more insights on travel related health issues please check our blog at Pyllola's website Please consider that this podcast is solely for informational purposes and should not be regarded as medical advice or a recommendation for any medication or treatment. It is essential that your doctor assesses your condition and, if necessary, prescribes the appropriate treatment.

Travel Health Podcasts by Pyllola"Travel Health" is the essential guide for healthcare tourism, maintaining well-being while exploring the globe! It is your in-pocket travel clinic and covers vital topics for travelers, including the management of chronic conditions and health risks abroad, dietary advice during travel, and prevalent travel-related illnesses. Our experts offer priceless knowledge, share their own experiences, and give practical advice to tackle health issues with particular emphasis on Italy.<a href="https://www.pyllola.com" rel="noopener noreferrer">Pyllola </a>is a primary care provider specialized in primary healthcare for tourists and travelers in Italy, offering instant medical care by English-speaking doctors via an online visit.Pyllola offers the best way to see a physician in Italy as a tourist assuring best healthcare for travelers.​for more insights on travel related health issues please check our <a href="https://www.pyllola.com/blog" rel="noopener noreferrer">blog </a>at <a href="https://www.pyllola.com" rel="noopener noreferrer">Pyllola's </a>websitePlease consider that this podcast is solely for informational purposes and should not be regarded as medical advice or a recommendation for any medication or treatment. It is essential that your doctor assesses your condition and, if necessary, prescribes the appropriate treatment.

Travel Health

The HaloHealth podcast is your go-to source for the latest trends and insights in the industry.

The HaloHealth podcast is your go-to source for the latest trends and insights in the industry.

The HaloHealth Podcast

The latest autism research news stories with ASF Chief Science Officer Alycia Halladay

diagnosis – ASF Weekly Science Podcasts

HerzWerk ist ein Podcast für Patienten, der sich mit typischen Herzerkrankungen beschäftigt. Moderiert von Medizinstudent Johannes Fischer und regelmäßig begleitet von Prof. Dr. Torsten Doenst, einem international anerkannten Herzchirurgen, bieten wir monatlich neue, leicht verständliche Folgen zu Themen wie KHK, Herzklappen und mehr. Perfekt für Patienten, Studenten und alle Medizininteressierten.

HerzWerk Herzchirurgie Jena

infancy – ASF Weekly Science Podcasts

Clinical experts across the globe share expertise on improving patient outcomes. For healthcare providers across the care spectrum: inpatient care, primary healthcare providers, EMS, and ongoing professional advancement through healthcare certification.

Heart360°

The ACG Pregnancy Monographs podcast series will delve into the latest advancements in management of gastrointestinal diseases in the pregnancy and the postpartum period. In each podcast our expert panel of gastroenterologists will provide insights into specific topics about GI health in pregnancy. Tune in to gain a deeper understanding and learn how to provide the best care for pregnant patients with GI conditions.

Medicine Podcasts / Page 277